Raul R Rodriguez sold $60k of RIGL
CEO, President at RIGEL PHARMACEUTICALS INC. 52,894 shares at an average of $1.14, traded Feb 2, 2024, filed Feb 6, 2024.
Score components
- +25RoleCEO
- +7Trade size$60k at market
- 0Share of holdings soldSold 2.5% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-24-000445, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2024 | SOpen-market sale Common Stock | -22,349 | $1.13 | $25k | 2,067,174 | Feb 6, 2024 |
| Feb 5, 2024 | SOpen-market sale Common Stock | -30,545 | $1.14 | $35k | 2,036,629 | Feb 6, 2024 |
Related signals
Other insiders at RIGEL PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 9Weak | RIGEL PHARMACEUTICALS INC | Kamil Ali-Jackson director | $88k 2,500 shares | -20% | |
| 8Weak | RIGEL PHARMACEUTICALS INC | Kamil Ali-Jackson director | $73k 2,500 shares | -17% | |
| 16Weak | RIGLsell RIGEL PHARMACEUTICALS INC | Walter H Moos director | $145k 4,000 shares | -24% | |
| 22Weak | RIGLsell RIGEL PHARMACEUTICALS INC | Raymond J. Furey EVP, GC, CCO & Corp Sec | $60k 2,787 shares | -7% | |
| 37Weak | RIGEL PHARMACEUTICALS INC | Dean L Schorno EVP & Chief Financial Officer | $14k 12,628 shares | -3% | |
| 30Weak | RIGEL PHARMACEUTICALS INC | David A Santos EVP, Chief Commercial Officer | $16k 14,519 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.